Moreover, the present study also indicated that regorafenib may inhibit tumor growth and progression via the suppression of the P2X7/PI3K/mTOR/NF-κB axis and dephosphorylation of p-p38 MAPK in MCF7 cells. Here, MTOR is linked to neoplasm.